During the ISPOR the PHARMO team had the opportunity to share our capabilities at the PHARMO booth and in our PHARMO meeting room. We presented 12 poster presentations and copresented the workshop “Retrospective health outcomes research and health-economic evaluation based on real-world data analyses in Europe: Data availability, strengths and limitations and database-specific considerations”.

Workshop

Our Manager Research Department, Myrthe van Herk-Sukel, copresented the workshop “Retrospective health outcomes research and health-economic evaluation based on real-world data analyses in Europe: Data availability, strengths and limitations and database-specific considerations (W16)” together with Thomas Wilke (Ingress-Health), Wilhelmine Meeraus (CPRD) and Andreas Fuchs (AOK PLUS).

This workshop showed a general overview of available retrospective health databases across Europe as there is a growing need to obtain real-world evidence/outcomes data in numerous indications to support regulatory, market access and clinical decision making. Retrospective database studies seem to be a fast and rather cost-effective option to collect these data. However, there may be disadvantages of database studies as well, i.e. because of limited availability of clinical data (in some databases), the mostly retrospective nature of data, non-representativeness of some databases and difficulty in assessing confounders.

As part of this workshop PHARMO presented the “PHARMO Database Network, Pros & cons in Oncology studies”. Subject was the strength of data linkage. No single database can fulfill all challenges in oncology studies and therefore linkage of databases is essential. The PHARMO Database Network comprises data for 25% of the residents in the Netherlands, with an average follow-up of 10 years.

The presentations are available at http://www.ispor.org/Event/ReleasedPresentations/2015Milan

Poster presentations

During the ISPOR, the PHARMO team presented 12 of our studies in the fields of diabetes, respiratory diseases, oncology and cardiovascular diseases:

Poster Presentations on Cardiovascular Disorders
- Anticoagulant treatment after VTE in the Netherlands

Poster Presentations on Cancer
- The effect of glucose lowering drug use on overall mortality among breast cancer patients
- Patterns of metachronous metastases after curative treatment of breast cancer
- Impact of cancer diagnosis and treatment on glycaemic control among individuals with colorectal cancer using glucose lowering drugs
- Changes in glucose lowering drug use before and after a cancer diagnosis among individuals with diabetes
- Drug use among elderly in the year before colon cancer diagnosis versus matched cancer-free controls
- Chemotherapy exposure and outcomes among patients diagnosed with chronic lymphoid leukemia

Poster Presentations on Respiratory-related disorders
- Prevalence of switching from brand to generic asthma medications

Poster Presentations on Diabetes/endocrine disorders
- Relationship between glycaemic burden and micro- and macrovascular complications in patients with type 2 diabetes mellitus: a real-world study in the Pharmo Database Network
- Factors associated with T2DM treatment choice across Europe
- Intensification of basal insulin treatment among patients with diabetes mellitus type 2 in the Netherlands
PHARMO attended the PhUSE 2015 Conference held from 11-14th October in Vienna, Austria. The theme of the Conference was ‘Clinical Data Science - From Data to Knowledge’.

Berber Snoeijer, R&D Manager at the PHARMO Institute, presented her work entitled ‘Working as a data scientist with real-world clinical data’. PHARMO also presented a study ‘Change in prevalence and distribution of DM type I and type II over time in the Netherlands’.

For more information about PhUSE, click here.

For more information about 25th ERS Congress, click here.

For more information about EASD, click here.
European Congress of Epidemiology - Healthy Living in Maastricht, the Netherlands, June 25-27, 2015

The PHARMO team was present at the European Congress of Epidemiology - Healthy Living in Maastricht, the Netherlands, June 25-27, 2015.

It was a great pleasure to present our study "Treatment Patterns and Outcomes of Patients Diagnosed with Ovarian Cancer in the Netherlands".

The European Congress of Epidemiology - Healthy Living brought together scientists from a broad range of health care fields. Topics included methodological developments and state-of-the-art applications of epidemiology in a variety of clinical and public health research settings all contributing to Healthy Living.

For more information about Healthy Living, click [here](#).

20th Congress of the European Hematology Association (EHA) in Vienna, Austria, June 11-14, 2015

We are pleased to announce that PHARMO contributed to a study which was presented at the EHA congress. The study is titled "Chemotherapy Exposure and Survival among Patients Diagnosed with Chronic Lymphoid Leukemia".

The EHA Annual Congress provides a forum for presenting original unpublished data and sharing ideas for hematological innovation as well as disseminating evidence-based knowledge of primary clinical relevance.

Hematologists and affiliated professionals attending the EHA Congress will be able to:

- Enhance their knowledge of evidence-based approaches on diagnosis and treatment for hematologic diseases.
- Access the latest results on clinical and translational research in hematologic disorders.
- Be updated on emerging innovative techniques, diagnostic tools and risk-assessment strategies in hematology and its subspecialties.
- Communicate, collaborate and network with representatives of a large international audience – medical professionals, national hematology societies, patient groups, medical industry and the media.

For more information about EHA 2015, click [here](#).
American Diabetes Association 75th Scientific Sessions

PHARMO contributed to a Post Authorization Safety Study which was presented at the 75th ADA Scientific Sessions, in Boston, June 5-9, 2015.

The study was entitled ‘Bladder cancer risk in relation to pioglitazone exposure among patients with T2DM – Pan European Multi-Database Study’. The study pooling results of four European countries did not find any evidence of an increased risk of bladder cancer with pioglitazone use.

The 75th Scientific Sessions brought together more than 18,000 total attendees including nearly 15,000 clinicians from all 50 states and 130 countries.

For more details, click here.

Joint Drug Information Association/European Medicines Agency information day on post-authorisation studies (PAS)

The PHARMO team was present at the Joint Drug Information Association/European Medicines Agency information day on post-authorisation studies (PAS) at the European Medicines Agency, London, UK on June 5, 2015.

Together with other contract research organisations, many of our clients and academic partners we explored regulatory procedures, requirements and scientific guidelines on the conduct of both safety and efficacy studies as well as the benefits of the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP), in which PHARMO is a partner, in supporting stakeholders in the conduct of PAS for regulatory decision making.

The information day also provided insights into current regulatory thinking about joint studies and how these could enhance a lifecycle approach to product development and benefit risk management.

For more information about the information day, click here

3rd annual Real World Evidence Europe, June 3-4, 2015

The PHARMO team was present at the Annual European Congress in Amsterdam, the Netherlands, June 3-4, 2015.

In its 3rd year, Real World Evidence EU was the ideal platform for your HTA/ payer engagement and showed you explicitly how to implement RWE into the core of your healthcare strategy. The PHARMO was pleased to meet you there.

PHARMO is an independent scientific research company that offers tailor-made data research, consultancy and IT solutions to support health outcomes, health economics, market access, and disease management strategies. We also assist our clients in their decision-making by performing risk/benefit assessment of drugs such as EMA-driven post-authorisation studies. We lead European studies to provide critical evidence in the context of emerging standards for study design, database and analysis operations, and quality assurance in Europe.

More information about Real World Evidence EU.
The PHARMO team attended the Prisma conference on Apps, pills & bytes – digitale farmaceutische patiëntenzorg van de toekomst'. Amersfoort, May 19th 2015.

The PHARMO team presented a descriptive pilot study on the availability of information on impaired renal function in the Dutch community pharmacies. This study shows that information availability on renal function is far from complete in patients with renal impairment and that major differences exist between pharmacies regarding information availability.

For an impression of the conference, click here

**ISPE 2015 Mid-Year Meeting**

PHARMO has been present at the ISPE Mid-Year Meeting, which was held from 12th to 14th April in Bordeaux, France.

Ron Herings held a presentation entitled *What to do with statins in the very elderly*.

For more details click here

---

**Vrijdag 6 februari 2015 - Promotie IKNL-onderzoeker Marjolein Zanders**

Aantal patiënten met kanker én diabetes neemt sterk toe

Het aantal mensen met kanker én diabetes type 2 is in Nederland sterk toegenomen. Inmiddels heeft bijna één op de vijf kankerpatiënten op het moment van kankerdiaagose ook al diabetes. Dit gegeven was aanleiding voor een proefschript naar de relatie tussen kanker en diabetes, waarop Marjolein Zanders (IKNL) vrijdag 6 februari 2015 promoveerde aan Tilburg University. Diabetespatiënten lijken ook vaker te overlijden na de diagnose kanker dan kankerpatiënten zonder diabetes. Zanders onderzocht de verschillen in behandeling en medicijengebruik om hierin meer inzicht te krijgen.

For more details, click here